Asthma is a chronic respiratory disease characterized by recurrent wheezing, shortness of breath, with or without chest tightness and cough. At present, drugs for treating asthma are mainly divided into control and relief categories.
Dipropylline Injection is a smooth muscle relaxant, and as a xanthine drug, it mainly relieves asthma attacks by relaxing the bronchi and coronary arteries. This product is mainly suitable for relieving wheezing symptoms in clinical practice, such as bronchial asthma, wheezing bronchitis, obstructive emphysema, etc. It is also used for asthma caused by cardiogenic pulmonary edema.
According to the data, dihydroxypropyl theophylline was developed by the Japanese company Eisai and was launched in Japan in 1952. As of now, the products of the original research enterprise have not been listed in China. This product is a Class B variety listed in the national medical insurance catalog.
Although dihydroxypropyl theophylline has various dosage forms such as tablets, injections, and suppositories, injections currently dominate the majority of the market. According to the official website of the National Medical Products Administration, there are currently 14 domestic enterprises with production approval documents for dihydroxypropyl theophylline injection. Among them, Sichuan Miaoji Biopharmaceutical and Shiyao Yinhu Pharmaceutical have passed the evaluation. In addition, according to the official website of the Drug Evaluation Center of the State Administration for Market Regulation, there are also three companies, Modern Hasen (Shangqiu) Pharmaceutical and Tianjin Pharmaceutical Heping (Tianjin) Pharmaceutical, whose consistency evaluation supplementary applications are under review. Forty five companies, including Shijiazhuang Siyao, Yangzhou Zhongbao Pharmaceutical, Zhejiang Thermo Pharmaceutical, and Chengdu Yuandong Biopharmaceutical, have applied for production under the three categories of imitation, and after approval, they will be deemed to have passed the evaluation.
It is understood that in recent years, the sales volume of dihydroxypropyl theophylline injection has grown rapidly. According to data from Mi Nei Net, in the first half of 2023, the sales volume of dihydroxypropyl theophylline injection in Chinese urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) increased by 151.26% year-on-year, exceeding the full year of 2022.
